Supplementary table 1: Innate immune response determinants of protection against WNV infection in mice.

Mouse strain	Survival (%)	Virologic phenotypes	Reference
WT (C57BL/6)	60-90	Virus in DLN, Sp, S, CNS No virus in K, Li, Ht, Lu, Mu	1-4
Proinflammatory cytokines			
Ifnar$^{-/-}$	0	↑ virus in DLN, Sp, S, CNS Enhanced tissue tropism (K, Li, Ht, Lu, Mu)	1
Ifn$\beta^{-/-}$	5	↑ virus in DLN, Sp, CNS Enhanced tissue tropism (K, Li, Ht, Lu)	5
Ifn$\gamma^{-/-}$	5	↑ virus in DLN, Sp, CNS No tissue tropism data reported	6
Ifnγ*R*$^{-/-}$	10	No virologic data reported	6
TnfRI$^{-/-}$	33	↑ virus in DLN, Sp, CNS No Δ in virus in S No tissue tropism data reported	7
PRR signaling components			
Dhx58$^{-/-}$	13.5	No Δ in virus in DLN, Sp ↑ virus in CNS No enhancement of tissue tropism (K)	8
Mavs$^{-/-}$	0	↑ virus in DLN, Sp, CNS Enhanced tissue tropism (K)	9
Irf1$^{-/-}$	0	↑ virus in DLN, Sp, S, CNS Enhanced tissue tropism (K)	10
Irf3$^{-/-}$	0	↑ virus in DLN, Sp, S, CNS Enhanced tissue tropism (K)	11
Irf7$^{-/-}$	0	↑ virus in DLN, Sp, S, CNS Enhanced tissue tropism (K)	12
Irf3$^{-/-}$ x *Irf7*$^{-/-}$	0	↑ virus in DLN, Sp, S, CNS Enhanced tissue tropism (K)	13
Tlr3$^{-/-}$	33	↑ virus in Sp, CNS Minor enhancement of tissue tropism (K)	14
Tlr7$^{-/-}$	9	↑ virus in CNS Enhanced tissue tropism (Li)	15
Myd88$^{-/-}$	15-29	↑ virus in DLN, Sp, CNS No Δ in virus S Enhanced tissue tropism (K)	15, 16
Antiviral effectors			
Ifit1$^{-/-}$	52	↑ virus in S No Δ in virus Sp, CNS No enhancement of tissue tropism (K)	17
Rsad2$^{-/-}$	18	↑ virus in Sp, CNS No Δ in virus DLN, S Enhanced tissue tropism (K)	18
RnaseI$^{-/-}$	51	↑ virus in DLN No Δ in virus S, Sp issue tropism not reported	19
PKR$^{-/-}$ x *RnaseI*$^{-/-}$	10	↑ virus in DLN, Sp, S, CNS No Δ in virus Sp, CNS Enhanced tissue tropism (Li)	19

Inflammasome			
Il1r$^{-/-}$	27	↑ virus in DLN, CNS No Δ in virus Sp, S No tissue tropism data reported	[20]
Nlrp3$^{-/-}$	42	↑ virus in CNS No data reported for DLN, Sp, S, and tissue tropism	[20]
Nlrc4$^{-/-}$	77	No virologic data reported	[20]
Caspase1$^{-/-}$	50	No virologic data reported	[20]
Complement			
C3$^{-/-}$	0	↑ virus in Sp, CNS No Δ in virus in S No tissue tropism data reported	[21]
C4$^{-/-}$	0	↑ virus S, CNS; ↓ virus in Sp, DLN No tissue tropism data reported	[22]
fB$^{-/-}$	4	↑ virus in Sp, CNS No Δ in virus in S, DLN No tissue tropism data reported	[22]
C1q$^{-/-}$	17	↑ virus in CNS ; ↓ virus in Sp, DLN No Δ in virus in S No tissue tropism data reported	[22]
C5$^{-/-}$	60	No virologic data reported	[23]
MBL-A$^{-/-}$xMBL-C$^{-/-}$	45	No Δ in virus in DLN, Sp, S, CNS No enhanced tissue tropism (K)	[24]

DLN, Draining lymph node; Sp, Spleen; S, Serum; K, Kidney; Li, Liver; Ht, Heart; Lu, Lung; Mu, Muscle; CNS, Central nervous system; Δ, change; ↑, increase; ↓, decrease.

1. Samuel, M.A. & Diamond, M.S. Type I IFN protects against lethal West Nile Virus infection by restricting cellular tropism and enhancing neuronal survival. *J Virol* **79**, 13350-13361 (2005).

2. Engle, M.J. & Diamond, M.S. Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice. *J Virol* **77**, 12941-12949 (2003).

3. Keller, B.C. et al. Resistance to alpha/beta interferon is a determinant of West Nile virus replication fitness and virulence. *J Virol* **80**, 9424-34 (2006).

4. Suthar, M.S., Brassil, M.M., Blahnik, G. & Gale, M., Jr. Infectious Clones of Novel Lineage 1 and Lineage 2 West Nile Virus Strains WNV-TX02 and WNV-Madagascar. *J Virol* **86**, 7704-9 (2012).

5. Lazear, H.M., Pinto, A.K., Vogt, M.R., Gale, M., Jr. & Diamond, M.S. Beta interferon controls West Nile virus infection and pathogenesis in mice. *J Virol* **85**, 7186-94 (2011).

6. Shrestha, B. et al. Gamma interferon plays a crucial early antiviral role in protection against West Nile virus infection. *J Virol* **80**, 5338-48 (2006).

7. Shrestha, B., Zhang, B., Purtha, W.E., Klein, R.S. & Diamond, M.S. Tumor necrosis factor-{alpha} protects against lethal West Nile virus infection by promoting trafficking of mononuclear leukocytes into the central nervous system. *J Virol* (2008).

8. Suthar, M.S. et al. The RIG-I-like Receptor LGP2 Controls CD8(+) T Cell Survival and Fitness. *Immunity* (2012).

9. Suthar, M.S. et al. IPS-1 is essential for the control of West Nile virus infection and immunity. *PLoS Pathog* **6**, e1000757 (2010).

10. Brien, J.D. et al. Interferon regulatory factor-1 (IRF-1) shapes both innate and CD8(+) T cell immune responses against West Nile virus infection. *PLoS Pathog* **7**, e1002230 (2011).

11. Daffis, S., Samuel, M.A., Keller, B.C., Gale, M., Jr. & Diamond, M.S. Cell-specific IRF-3 responses protect against West Nile virus infection by interferon-dependent and independent mechanisms. *PLoS Pathog* **3**, e106 (2007).

12. Daffis, S. et al. Interferon regulatory factor IRF-7 induces the antiviral alpha interferon response and protects against lethal West Nile virus infection. *J Virol* **82**, 8465-75 (2008).

13. Daffis, S., Suthar, M.S., Szretter, K.J., Gale, M., Jr. & Diamond, M.S. Induction of IFN-beta and the innate antiviral response in myeloid cells occurs through an IPS-1-dependent signal that does not require IRF-3 and IRF-7. *PLoS Pathog* **5**, e1000607 (2009).

14. Daffis, S., Samuel, M.A., Suthar, M.S., Gale, M., Jr. & Diamond, M.S. Toll-like receptor 3 has a protective role against West Nile virus infection. *J Virol* **82**, 10349-58 (2008).

15. Town, T. et al. Toll-like receptor 7 mitigates lethal West Nile encephalitis via interleukin 23-dependent immune cell infiltration and homing. *Immunity* **30**, 242-53 (2009).

16. Szretter, K.J. et al. The innate immune adaptor molecule MyD88 restricts West Nile virus replication and spread in neurons of the central nervous system. *J Virol* **84**, 12125-38 (2010).

17. Szretter, K.J. et al. 2'-O methylation of the viral mRNA cap by west nile virus evades ifit1-dependent and -independent mechanisms of host restriction in vivo. *PLoS Pathog* **8**, e1002698 (2012).

18. Szretter, K.J. et al. The interferon-inducible gene viperin restricts West Nile virus pathogenesis. *J Virol* **85**, 11557-66 (2011).

19. Samuel, M.A. et al. PKR and RNase L contribute to protection against lethal West Nile Virus infection by controlling early viral spread in the periphery and replication in neurons. *J Virol* **80**, 7009-7019 (2006).

20. Ramos, H.J. et al. IL-1β signaling promotes CNS-intrinsic immune control of west nile virus infection. *PLoS Pathog* ***In press*** (2012).

21. Mehlhop, E. et al. Complement activation is required for the induction of a protective antibody response against West Nile virus infection. *J Virol* **79**, 7466-7477 (2005).

22. Mehlhop, E. & Diamond, M.S. Protective immune responses against West Nile virus are primed by distinct complement activation pathways. *J Exp Med* **203**, 1371-81 (2006).

23. Mehlhop, E., Fuchs, A., Engle, M. & Diamond, M.S. Complement modulates pathogenesis and antibody-dependent neutralization of West Nile virus infection through a C5-independent mechanism. *Virology* **393**, 11-5 (2009).

24. Fuchs, A., Pinto, A.K., Schwaeble, W.J. & Diamond, M.S. The lectin pathway of complement activation contributes to protection from West Nile virus infection. *Virology* **412**, 101-9 (2011).